%0 Journal Article %T Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy %+ University of California Medical Center [San Diego] (UCMC) %+ University of Pittsburgh (PITT) %+ Hypoxie et PhysioPathologie (HP2) %+ CHU Grenoble %+ St. Luke's Hospital [Chesterfield, MO, USA] (SLH) %+ Leiden University Medical Center (LUMC) %+ Sahlgrenska University Hospital [Gothenburg] %+ University of Gothenburg (GU) %+ Brigham and Women's Hospital [Boston] %+ Harvard University %+ Jazz Pharmaceuticals [Palo Alto, CA, USA] (JP) %+ Case Western Reserve University [Cleveland] %A Malhotra, Atul %A Strollo, Patrick %A Pépin, Jean-Louis %A Schweitzer, Pierre %A Lammers, Joris %A Hedner, Jan %A Redline, Susan %A Chen, D %A Chandler, Paul %A Bujanover, S %A Strohl, Kingman %< avec comité de lecture %@ 1389-9457 %J Sleep Medicine %I Elsevier %V 100 %P 165-173 %8 2022 %D 2022 %R 10.1016/j.sleep.2022.08.005 %M 36084494 %K JZP-110 %K Lung %K Obesity %K Sleep apnea %K Solriamfetol %K Sunosi %Z Life Sciences [q-bio]Journal articles %X Objectives: This analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (Sunosi™) 37.5 (OSA only), 75, 150, or 300 mg/d.Methods: In two 12-week, randomized, placebo-controlled trials and one 1-year open-label extension study, changes in weight were evaluated from baseline to end of study (week 12 or week 40 of the open-label extension [after up to 52 weeks of solriamfetol treatment]) in participants with OSA or narcolepsy.Results: After 12 weeks of solriamfetol treatment, median percent change in weight from baseline across all solriamfetol doses was -0.84%, compared with 0.54% for placebo, in participants with OSA; and -0.07%, compared with 3.08% for placebo, in participants with narcolepsy. After up to 52 weeks of solriamfetol treatment, overall median percent change in weight from baseline was -1.76%, which showed a dose-dependent pattern (75 mg, 0.57%; 150 mg, -1.2%; 300 mg, -2.5%). Results were similar in subgroups of participants with OSA or narcolepsy, with overall median percent changes in weight of -2.2% and -1.1%, respectively. After up to 52 weeks of solriamfetol treatment, the percentage of participants with weight loss ≥5% relative to baseline was 25.7% overall and increased in a dose-dependent manner (75 mg, 4.5%; 150 mg, 17.3%; 300 mg, 32.4%). Results were similar among subgroups of participants with OSA or narcolepsy, with 26.4% and 24.2% of participants experiencing weight loss ≥5%, respectively. No weight-related treatment-emergent adverse events were serious.Conclusions: Solriamfetol treatment was associated with decreases in body weight in a dose-related manner. %G English %2 https://inserm.hal.science/inserm-03793913/document %2 https://inserm.hal.science/inserm-03793913/file/1-s2.0-S1389945722011005-main.pdf %L inserm-03793913 %U https://inserm.hal.science/inserm-03793913 %~ INSERM %~ UGA %~ UGA-EPE